Brief: Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day
11/12/2025 12:38
Dec 11 (Reuters) - Roivant Sciences Ltd ROIV.O: ROIVANT HIGHLIGHTS CONTINUED PIPELINE PROGRESS AND OUTLOOK FOR COMPANY’S NEXT PHASE OF GROWTH AT 2025 INVESTOR DAY ROIVANT SCIENCES LTD - BREPOCITINIB NDA FILING EXPECTED EARLY 2026, LAUNCH IN 2027 ROIVANT SCIENCES LTD - BREPOCITINIB PHASE 3 TRIAL IN NIU FULLY ENROLLED, DATA EXPECTED H2 2026 ROIVANT SCIENCES LTD - IMVT-1402 TRIAL IN D2T RA TOPLINE DATA EXPECTED 2026 Source text: ID:nGNX3LqfMN Further company coverage: ROIV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple